This is a summary of the European public assessment report (EPAR) for Siklos. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Siklos.
Therapeutic Indication
### Therapeutic indication Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.
Therapeutic Area (MeSH)
ATC Code
L01XX05
ATC Item
hydroxycarbamide
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| hydroxycarbamide | N/A | 羟基脲 |
EMA Name
Siklos
Medicine Name
Siklos
Aliases
N/A